CN1318077C - Antivirus Chinese medicine compound preparation and its preparation method - Google Patents

Antivirus Chinese medicine compound preparation and its preparation method Download PDF

Info

Publication number
CN1318077C
CN1318077C CNB2004101008416A CN200410100841A CN1318077C CN 1318077 C CN1318077 C CN 1318077C CN B2004101008416 A CNB2004101008416 A CN B2004101008416A CN 200410100841 A CN200410100841 A CN 200410100841A CN 1318077 C CN1318077 C CN 1318077C
Authority
CN
China
Prior art keywords
preparation
parts
medicine
drying
effect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2004101008416A
Other languages
Chinese (zh)
Other versions
CN1650993A (en
Inventor
余华
钟小群
张爱华
方铝
李玉云
张俊明
翁秀英
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Lingbao Pharmaceutical Co ltd
Original Assignee
Jiangxi Medicine Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangxi Medicine Research Institute filed Critical Jiangxi Medicine Research Institute
Priority to CNB2004101008416A priority Critical patent/CN1318077C/en
Publication of CN1650993A publication Critical patent/CN1650993A/en
Application granted granted Critical
Publication of CN1318077C publication Critical patent/CN1318077C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

The present invention relates to a sort of antivirus compound Chinese medicine, whose raw material includes: forsythia, arctium fruit, honeysuckle, belamcanda rhizome, pull ball and phragmites communis trin. The prescription of the invention is base on the ancient prescription of YINQIAOMABOSAN, and this medicine is made using the modern technological process. It can be prepared to any acceptable dosage form which is acceptable in pharmacy. The present invention also relates to the making method and new usage of this medicine. The beneficial effect of this medicine includes: Proved by experiment, the medicine of the invention have a prominent antivirus action. It has an evident antivirus effect of respiratory tract which is proved by a serious of experiments in vivo (mouse) and external experiments (cell), and it is close to the experiment results of the Shuanghuanglian oral liquid and ribavirin test; indicated by the external experiment of restraining the virus of atypical pneumonia, the restrain effect to the coronaviruses 04 in the cell V E R O E6 is weaker than the ganciclovir, and it is only one thirty-second of the contrast medicine. Because it has heat-clearing and antitoxic effect, anti-inflammatory action, antibacterial effect and the like pharmacological effect, it has an auxiliary effect for treating the atypical pneumonia.

Description

A kind of antiviral compound Chinese medicinal preparation and its production and use
Technical field
The present invention relates to a kind of antiviral compound Chinese medicinal preparation, is serve as the medicine that the basis adopts the modern crafts method to prepare with ancient prescription " YINQIAO Lasiosphaera Seu Calvatia loose " specifically, and antiviral experimental results show that this medicine has tangible antivirus action.The invention still further relates to the preparation method of this medicine, and the new purposes in preparation antiviral, especially respirovirus and SARS medicine for treating viral infections.
Background technology
The epidemic febrile disease of indication in motherland's traditional medicine is the general name of 4 o'clock evil caused various acute calentura of various warm or damp and hot poison of impression.In hygropyrexia, larynx resistance pharyngalgia is early stage symptom, calls acute tonsillitis in the Chinese medicine again, also is equivalent to the acute tonsillitis in the modern medicine.Acute tonsillitis is a commonly encountered diseases, a frequently-occurring disease clinically, and good sending out in child and teenager shows according to epidemiology statistics, have an appointment in the Childhood commonly encountered diseases 60% to be respiratory tract disease, and wherein about 80% is acute tonsillitis.The western medical treatment acute tonsillitis mainly is to add symptomatic treatment with antibiotics, and this Therapeutic Method very easily causes the antibiotics abuse and some untoward reaction take place.Motherland's medical science often adopts heat-clearing and toxic substances removing when the treatment epidemic febrile disease, let out lung sore-throat relieving method, obtains satisfactory effect.Clearly. the ancient prescription of Wu's a kind of jade work " Wenbing Tiaobian, Detailed Analysis of Epidemic Warm Diseases " record---YINQIAO Lasiosphaera Seu Calvatia looses has significant curative effect to the treatment acute tonsillitis, and original text is recited as " hygropyrexia larynx resistance pharyngalgia, the YINQIAO Lasiosphaera Seu Calvatia looses the master's ".The YINQIAO Lasiosphaera Seu Calvatia looses and to be made up of Fructus Forsythiae, Fructus Arctii, Flos Lonicerae, Rhizoma Belamcandae, Lasiosphaera Seu Calvatia, and the effect heat-clearing and toxic substances removing is let out the lung sore-throat relieving, and doctor family is many to hinder with its treatment hygropyrexia larynx that all cards of red swelling and pain of throat have good effect due to pharyngalgia or affection due to external wind and heat, the pyretic toxicity.IS-One is loose with the YINQIAO Lasiosphaera Seu Calvatia and is made electuary, treatment acute tonsillitis and acute suppurative tonsillitis 329 examples, 232 examples of fully recovering (70.52%), 9 examples that take a turn for the better (27.05%), invalid 8 examples (2.43%), total effective rate 97.4%[China combination of Chinese and Western medicine magazine 1995; 15 (7)].Cai Shi looses with the YINQIAO Lasiosphaera Seu Calvatia and adds and subtracts treatment acute tonsillitis 36 examples, produce effects 21 examples (58.3%), and effective 13 examples (36.1%), invalid 2 examples (5.6%), total effective rate is a 94.4%[Jiangxi Chinese medicine, 2001; 32 (5)].Deng Shi looses with the YINQIAO Lasiosphaera Seu Calvatia and treats paediatric acute tonsillitis 60 examples, 51 examples of fully recovering (85.0%), and effective 7 examples (11.7%), invalid example (3.3%), total effective rate is a 96.7%[Jiangxi Chinese medicine, 2000; 31 (6)].Though we are used for the treatment of acute tonsillitis clinically tangible curative effect is arranged, but the conventional dosage forms of this prescription is a water decoction, its quality can not be controlled, retention is low, patient needs to decoct by doctor's advice and take a large amount of water decoctions, and dose greatly particularly child is taken medicine inconvenience is arranged more, and it is poor to take mouthfeel, limited its application, also the incompatibility market demand.
On the other hand, according to investigation, record the Chinese patent medicine of 59 acute and chronic tonsillitiss of treatment and pharyngitis at present in " national drug standards ", but only there be clear and definite its of 'Shuang Hualian ' injection agent to have antiviral efficacy, only account for 1.7%, and other Chinese patent medicine all clearly do not carry and has " antiviral " effect, and this mostly is to prove in default of the pharmacodynamics data.Certainly the Chinese patent medicine that the experimental technique proof that also is out of use is made with these prescriptions has tangible antivirus action, therefore can only carry it in the operation instructions clinically and have heat-clearing and toxic substances removing, let out the effect of lung sore-throat relieving, can not indicate that it has " antiviral " effect with the language of modern medicine.So also limited to the effect when clinical use.
Summary of the invention
The shortcoming that the objective of the invention is above-mentioned in order to overcome " YINQIAO Lasiosphaera Seu Calvatia loose " Chinese medicine name side decoction provides a kind of Chinese patent medicine preparation of safe and effective, quality controllable, taking convenience for larynx resistance pharyngalgia patient.Use the method for pharmacological evaluation simultaneously, prove that medical instrument of the present invention has " antiviral " effect, clearly increases " antiviral " clinical scope of application of medicine of the present invention.Another purpose provides the preparation method and the new purposes thereof of medicine of the present invention.
The present invention is achieved in that preparation of the present invention is prepared from by following raw medicaments in portion by weight:
1～10 part of 3～15 parts of Lasiosphaera Seu Calvatia of 5～25 parts of Rhizoma Belamcandae of 6～30 portions of Flos Loniceraes of 10～50 parts of Fructus Arctiis of Fructus Forsythiae
In preparation of the present invention, its crude drug also can add 5～20 parts of Rhizoma Phragmitiss.
The preferred weight ratio scope of above-mentioned raw materials medicine is:
7～15 parts of 3～8 parts of Rhizoma Phragmitiss of 5～12 parts of Lasiosphaera Seu Calvatia of 10～20 parts of Rhizoma Belamcandae of 9～24 portions of Flos Loniceraes of 15～40 parts of Fructus Arctiis of Fructus Forsythiae
The weight ratio scope of above-mentioned raw materials medicine is preferred:
7.52 parts of 7.52 parts of Lasiosphaera Seu Calvatia of 12.48 parts of Rhizoma Belamcandae of 15 portions of Flos Loniceraes of 25 parts of Fructus Arctiis of Fructus Forsythiae
The weight ratio scope of above-mentioned raw materials medicine is also preferred:
10 parts of 6 parts of Rhizoma Phragmitiss of 9 parts of Lasiosphaera Seu Calvatia of 15 parts of Rhizoma Belamcandae of 18 portions of Flos Loniceraes of 30 parts of Fructus Arctiis of Fructus Forsythiae
The preparation method of preparation of the present invention is as follows:
(1), get each crude drug, add 1～20 times of water gaging, heating extraction 3 times, each 0.5～3 hour, merge 3 times the water extract, filter, filtrate concentrates;
(2), adding 95% ethanol, to transfer pure content be 30～75%, places, centrifugal;
(3), get supernatant and add the beta-schardinger dextrin-inclusion, stirring evenly the back decompression and solvent recovery and being concentrated into relative density is 1.04～1.60 clear paste, centrifugally goes out beta-cyclo dextrin included compound, drying is pulverized, and crosses 80 mesh sieves;
(4), with above-mentioned dry thing, make acceptable various dosage forms on the pharmaceutics according to a conventional method.
The dosage form of preparation of the present invention comprises for example granule, capsule, tablet, oral liquid, pill, suspensoid, drop pill, pellet, buccal tablet, soft gelatin capsule, soft capsule, dispersible tablet, solution, aerosol, spray, cataplasma or patch etc.
In above-mentioned preparation technology:
Method for concentration can be to concentrate under the normal pressure, also can be concentrating under reduced pressure, and the concentrating under reduced pressure condition is: 0.01～0.09MPA, 40～90 ℃;
Reclaiming solvent method can be that normal pressure reclaims, and also can be reclaim under reduced pressure, and the condition of decompression and solvent recovery is: 0.01～0.09MPA, 30～80 ℃;
Drying means can be: contact drying, pneumatic conveying drying, tunnel type oven drying, vacuum (decompression) drying, airpillow-dry, spray drying, lyophilization, far-infrared ray drying, microwave drying.
The preparation method of preparation of the present invention is preferred: get crude drug Rhizoma Belamcandae, Fructus Arctii, Lasiosphaera Seu Calvatia, Flos Lonicerae and Fructus Forsythiae, add 10 times of water gagings, 90-95 ℃ of heating extraction three times, each 1h, merge the water extract, filter, filtrate concentrates below 80 ℃ and is cooled to 40 ℃ must relative density be the clear paste of 1.06-1.07; Add ethanol and transfer and to contain the alcohol amount and reach 50%, stir evenly, placement is spent the night, and is centrifugal; Get supernatant and add beta-schardinger dextrin-, stir evenly, 70 ℃, decompression recycling ethanol under the 0.07Mpa condition, and be concentrated into the medicinal liquid that relative density is 1.10-1.15, and standing over night, centrifugal, supernatant is stand-by; Be deposited in 70-80 ℃ of oven dry, pulverize, cross 80 mesh sieves, add cane sugar powder, mixing is made granule with one step of supernatant, and making particulate technological parameter is 80 ℃ of intake air temperatures, 50 ℃ of air outlet temperature, and granulate, packing, promptly.
We's five kinds of Chinese medicine, Fructus Forsythiae, Flos Lonicerae are monarch drug, and Fructus Arctii, Lasiosphaera Seu Calvatia are ministerial drug, and Rhizoma Belamcandae is a messenger drug, and wherein Lasiosphaera Seu Calvatia is the fungus medical material, is used as medicine with sporinite, character is different with other five tastes.Therefore, consider that the Lasiosphaera Seu Calvatia list carries, because Lasiosphaera Seu Calvatia does not have characteristic component, mainly adopting dried cream yield is index, in conjunction with definite optimum conditions such as the color and luster of dried cream, abnormal smells from the patient, meltings.All the other five tastes, one of Fructus Forsythiae effective ingredient are phillyrin, and the main effective ingredient of Flos Lonicerae is a chlorogenic acid, and Fructus Arctii contains arctiin, and Rhizoma Belamcandae contains flavone compound etc.By measuring index components such as volatilization oil mass, total flavones, chlorogenic acid, phillyrin, arctiin, calculate the rate of transform, compare extracting method such as steam distillation, ethanol refluxing process, alcohol percolation method, water extraction method, in conjunction with factors such as the yield of dried cream, color and luster, meltings, overall merit is selected optimum extraction process.
Steam distillation: Fructus Forsythiae 60g, Flos Lonicerae 30g press Chinese Pharmacopoeia version essential oil extraction method in 2000 and extract volatile oil, and extraction time 5-10 hour, filter, medicinal liquid is standby.Medicinal residues and Fructus Arctii 36g, Rhizoma Belamcandae 18g, Lasiosphaera Seu Calvatia 18g, 6-14 times of decocting boils 3 times, each 0.5-2h, filter, merging filtrate was concentrated to 1: 1, add 95% ethanol, accent contains alcohol to be measured to 50-70%, stirs evenly, standing over night, centrifugal, filter, get filtrate, merge extractive liquid,, decompression recycling ethanol, drying under reduced pressure, powder 20.95g gets dry extract.
Ethanol refluxing process: take by weighing Fructus Forsythiae 30g, Flos Lonicerae 15g, Fructus Arctii 18g, Rhizoma Belamcandae 9g, Lasiosphaera Seu Calvatia 18g mixing, totally three parts, add the 50%-70% alcohol reflux 3 times that 6-14 doubly measures respectively, each 0.5-2h, merge three times filtrate, drying under reduced pressure behind the decompression and solvent recovery, pulverize the powder that gets dry extract, weigh.Take by weighing an amount of dried cream powder respectively, measure These parameters in accordance with the law, the results are shown in Table 1.
Alcohol percolation method: take by weighing Fructus Forsythiae 30g, Flos Lonicerae 15g, Fructus Arctii 18g, Rhizoma Belamcandae 9g, Lasiosphaera Seu Calvatia 18g coarse powder, mixing, pack in the percolator, add 50%-70% ethanol, carry out percolation in accordance with the law, collect percolate to color light (volume is about heavy 15 times of medical material), reclaim ethanol respectively, drying under reduced pressure is pulverized the powder that gets dry extract.Take out an amount of dried cream powder respectively and carry out These parameters mensuration in accordance with the law,
Extraction process of the present invention: take by weighing Fructus Forsythiae 30g, Flos Lonicerae 15g, Fructus Arctii 18g, Rhizoma Belamcandae 9g, add 6-14 times of water gaging, 60-95 ℃ of heating extraction three times, each 0.5-2h merges the water extract, filters, it is centrifugal that filtrate concentrates, extracting centrifugal liquid and the Lasiosphaera Seu Calvatia leaching liquid merging drying under reduced pressure powder that gets dry extract.
The selection process of preparation of the present invention is: add 10 times of water gagings, 90-95 ℃ of heating extraction three times, each 1h merges the water extract, filter, filtrate concentrate below 80 ℃ be cooled to 40 ℃ relative density is the clear paste of 1.06-1.07; Add ethanol and transfer and to contain the alcohol amount and reach 50%, stir evenly, placement is spent the night, and is centrifugal; It is an amount of to get supernatant adding beta-schardinger dextrin-, stir evenly, and 70 ℃, decompression recycling ethanol under the 0.07Mpa condition, and be concentrated into the medicinal liquid that relative density is 1.10-1.15, and standing over night, centrifugal, supernatant is stand-by; Be deposited in 70-80 ℃ of oven dry, pulverize, cross 80 mesh sieves, the adding Icing Sugar is an amount of, and mixing is made granule with one step of supernatant, and making particulate technological parameter is 80 ℃ of intake air temperatures, 50 ℃ of air outlet temperature, and granulate, packing, promptly.
Each extracting method of table 1 relatively
Volatilization oil mass ml (%) Dried cream g (yield) Chlorogenic acid mg (rate of transform) Arctiin mg (rate of transform) Phillyrin mg (rate of transform) Flavone g (rate of transform) Color and luster Melting
Medicinal material (182g) steam distillation ethanol refluxing process alcohol percolation method 0.50 (0.55) 20.97 (11.52％) ) 18.20 (20.00％ ) 16.12 (17.71％ ) 579.00 (100％) 177.9 0 (30.72％) 179.84 (62.12％) 218.86 (75.60％) 2066.40 (100％) 1293.51 (62.60％) 730.90 (70.74％) 856.42 (82.89％) 114.00 (100％) 43.14 (31.84％) 35.06 (61.50％) 39.27 (68.89％) 9.6g (100％) 4.77 (49.69％ ) 4.34 (90.41％ ) 4.52 (94.42％ ) Sepia dark brown dark brown + ++ +
Extraction process of the present invention 15.2 (16.70％ ) 189.68 (65.52％) 774.08 (74.92％) 38.82 (68.10％) 4.37 (91.04％ ) Brown -
Annotate :-: no breeze dissolved; +: dissolve micro-breeze; ++: dissolve a small amount of breeze.
The every index of overall merit determines that extraction process of the present invention is an optimum process.
The isolation and purification method
At present Chinese medicine preparation preparation process isolation and purification method commonly used for filter, methods such as centrifugal, ultrafiltration, natural precipitant method, macroporous resin adsorption desorption method, alcohol precipitation.For obtaining the comparatively separation purifying technique of science, the system of selection 1 pure sedimentation method, method 2 natural precipitant methods, method 3 ultrafiltrations, these 4 kinds of methods of method 4 centrifuging compare research, with the isolation and purification method of selecting to be fit to.
Branch is got the about 0.2g of dried cream powder that above 4 kinds of technologies obtain as a result, carries out every index determining, the results are shown in Table 2
The different separation purifying technique results of table 2
Method Dried cream g (yield) Chlorogenic acid mg (rate of transform) Arctiin mg (rate of transform) Phillyrin mg (rate of transform) Total flavones (g) is (rate of transform) (n=3-5) Appearance character
Medical material (91g) 1234 10.46 (11.49％) 15.50 (17.03％) 13.19 (14.49％) 15.60 (17.14％) 289.50 (100％) 171.90 (59.38％) 197.70 (68.29％) 185.19 (63.97％) 191.70 (66.22％) 1033.20 (100％) 590.35 (57.14％) 647.45 (62.66％) 633.47 (61.31％) 77 0.50 (74.57％) 57.00 (100％) 30.33 (53.21％) 35.69 (62.61％) 34.16 (59.9 3％) 36.63 (64.26％) 4.8 (100％) 3.64 (75.83％) 4.19 (87.29％) 4.17 (86.88％) 4.37 (91.04％) Brown, it is brown to be difficult for the moisture absorption, very easily the moisture absorption is brown, very easily the moisture absorption is brown, very easily the moisture absorption
Separation, purification process result of study: the pure sedimentation method reduce dried cream yield, but the active ingredient rate of transform is lower slightly, consider the industrialized suitability, so method for selecting 1.
By extracting method with separate, purification process research more finally determines method for making of the present invention, repeats second trial by the technology of this method for making, the results are shown in Table 3.
Table 3 separates, purification process research is compared
Technology Dried cream gram (yield) Chlorogenic acid milligram (rate of transform) Arctiin milligram (rate of transform) Phillyrin milligram (rate of transform) Total flavones gram (rate of transform)
Medical material sample 1 sample 2 is average 13.64(14.99％ ) 13.73(15.09％ ) 13.68(15.04％ ) 289.50(100％) 187.07(64.62％ ) 191.65(66.20％ ) 188.87(65.24) 1033.20(100％) 746.07(72.21％ ) 738.74(71.50％ ) 742.35(71.85％ ) 57.00(100％) 29.36(51.50％ ) 28.44(49.90％ ) 28.90(50.70％ ) 4.80(100％) 3.58(74.58％) 3.49(72.71％) 3.54(73.75％)
By table as seen, method for making favorable reproducibility of the present invention can adapt to suitability for industrialized production.
The beneficial effect of medicine of the present invention shows:
Prove that through pharmacodynamics test medicine of the present invention has tangible antiviral, antiinflammatory, bacteriostasis.Be particularly useful for being used for anti-respirovirus and SARS virus.Concrete test is as follows:
1, antivirus action:
(mice) and external (cell) campaign proves that silver-colored horse antiviral drugs has the effect of tangible preventing respiratory viruses in body, and is approximate with positive control drug SHUANGHUANGLIAN KOUFUYE and ribavirin result of the test.Through the medicine efficacy screening test of vitro inhibition SARS virus, adopt the CPE method, its therapeutic index is 2.
(1), the external preventing respiratory viruses test of pesticide effectiveness of medicine of the present invention:
1., influenza first 3 types virus test: in Testis et Pentis Canis passage cell (mdck cell), drug toxicity is tested positive control drug SHUANGHUANGLIAN KOUFUYE and ribavirin.The results are shown in Table 4.
Table 4 silver horse antiviral drugs influenza first 3 types virus result of the test
Medicine Method The single administration group Three administration groups
IC 50μg/ml MIC μg/ml TI IC 50μg/ml MIC μg/ml TI
Silver horse antiviral drugs CPE method mtt assay 19±0.6 22±2.6 46.9±0 46.9±0 115 94.9 17±0.9 20±3.8 46.9±0 46.9±0 127 102
SHUANGHUANGLIAN KOUFUYE CPE method mtt assay 18±4.8 17.7±4 46.9±0 46.9±0 136 117 ＞11.7±0 ＞11.7±0 23.4±0 23.4±0 ＜202 ＜172
Ribavirin CPE method mtt assay 17±0.9 18.6±5.3 46.9±0 46.9±0 ＞176 ＞173 15±0.6 17±0.3 46.9±0 46.9±0 ＞196 ＞175
2., anti-Ad3 virus test: in people's pulmonary carcinoma passage cell (293 cell) and human cervical carcinoma cell (Hela cell), drug toxicity is tested positive control drug SHUANGHUANGLIAN KOUFUYE and ribavirin.The results are shown in Table 5.
The anti-Ad3 virus of table 5 silver horse antiviral drugs result of the test
Medicine Cell Method The single administration group Three administration groups
IC 50μg/ml MIC μg/ml TI IC 50μg/ml MIC μg/ml TI
Silver horse antiviral drugs 293 cells CPE method mtt assay 17.7±1.9 18.8±0.8 46.9±0 46.9±0 112 108 15.9±0.6 18±0.3 46.9±0 46.9±0 134 110
SHUANGHUANGLIAN KOUFUYE CPE method mtt assay 14.6±0.7 21±1.4 46.9±0 46.9±0 179 81 ＜11.7±0 ＜14±0.6 46.9±0 23.4±0 224 126
Ribavirin CPE method mtt assay 15.8±1.4 19±0.9 46.9±0 46.9±0 190 158 15±0.3 19±3.9 46.9±0 46.9±0 198 159
Silver horse antiviral drugs The Hela cell CPE method mtt assay 25.5±2 28.9±9.7 93.8±0 78.1±27 84 78.2 18±1.4 19±3.9 62.5±27 31.3±13.5 118 109
SHUANGHUANGLIAN KOUFUYE CPE method mtt assay 14±0.3 22±1.1 46.9±0 31.3±13. 5 173 77 ＜11.7±0 ＜11.7±0 23.4±0 23.4±0 213 146
Ribavirin CPE method mtt assay 17.8±0.6 23.8±0.7 78.1±27 46.9±0 168 126 14.8±2.6 17.7±0.6 46.9±0 46.9±0 207 170
3., anti-RSV virus test: in African green monkey kidney cell (Vero cell) and people's pharyngeal cancer epithelial cell (Hep-2 cell), drug toxicity is tested positive control drug SHUANGHUANGLIAN KOUFUYE and ribavirin.The results are shown in Table 6.
The anti-RSV virus of table 6 silver horse antiviral drugs result of the test
Medicine Cell Method The single administration group Three administration groups
IC 50μg/ml MIC μg/ml TI IC 50μg/ml MIC μg/ml TI
Silver horse antiviral drugs The Vero cell CPE method mtt assay 18±1.6 20±0.8 46.9±0 23.4±0 119 106 16±1.9 22.5±0.5 46.9±0 23.4±0 132 94
SHUANGHUANGLIAN KOUFUYE CPE method mtt assay 12±0.5 21±1.4 46.9±0 23.4±0 246 86 ＜11.7±0 ＜11.7±0 23.4±0 23.4±0 ＞258 ＞153
Ribavirin CPE method mtt assay 16±0.5 21±0.8 46.9±0 23.4±0 184 140 12.9±1.2 23±0.8 39±14 23.4±0 232 129
Silver horse antiviral drugs The Hep-2 cell CPE method mtt assay 23.7±5.2 25.8±8.6 93.8±0 78.1±27 94 84 16.9±1 18.7±0 46.9±0 23.4±0 127 109
SHUANGHUANGLIAN KOUFUYE CPE method mtt assay 12.8±0 21.3±1.2 46.9±0 31.3±13. 5 225 82 ＜11.7±0 ＜11.7±0 23.4±0 11.7±0 ＞246 ＞149
Ribavirin CPE method mtt assay 19.6±3.8 21±1.8 78.1±27 54.7±35. 8 158 144 18±1.9 17.5±0.5 78.1±27 39±13.5 167 171
(2), the resisiting influenza virus test of pesticide effectiveness in the medicine body of the present invention
1., give influenza virus after, observe 14 days according to each the group dead mouse count statistical result, positive control drug SHUANGHUANGLIAN KOUFUYE and ribavirin.The results are shown in Table 7.
Resisiting influenza virus result of the test (is index with the mortality rate) in the table 7 silver horse antiviral agents object
Medicine Dosage (g/kg) Number of mice (only) Survival number (only) Death toll (only) Mortality rate (%) Protective rate (%) Statistical procedures Interpretation of result * median effective dose (ED 50)
X 2 P
Silver horse antiviral drugs shuanghuanglian mixture, shuanghuanglian koufuye Ribavirin 4 2 1 0.5 4 2 1 0.5 0.1 0.05 0.025 30 30 30 30 30 30 30 30 30 30 30 30 29 23 17 23 19 17 10 30 30 24 0 1 7 13 7 11 13 20 0 0 6 0 3 23 43 23 37 43 67 0 0 20 100 97 75 54 75 60 54 28 100 100 78 52.50 48.65 30.24 17.33 30.24 21.17 17.33 6.66 52.50 52.50 33.85 ＜0.01 ＜0.01 ＜0.01 ＜0.01 ＜0.01 ＜0.01 ＜0.01 ＜0.01 ＜0.01 ＜0.01 ＜0.01 There is remarkable result to have remarkable result to have remarkable result to have remarkable result to have remarkable result to have remarkable result to have the remarkable result remarkable result that produced effect to have remarkable result that remarkable result is arranged ＜0.5 g/kg 0.93 g/kg ＜0.025 g/kg
Virus control 10 LD 50 30 2 28 93
*Calculate according to protective rate
2., give influenza virus after, observing 14 days is the indicator-specific statistics result according to each group life of mouse rate, positive control drug SHUANGHUANGLIAN KOUFUYE and ribavirin.The results are shown in Table 8
Resisiting influenza virus result of the test in the table 8 silver horse antiviral agents object (is index to prolong vital rates)
Medicine Dosage (g/kg) Number of mice (only) Mortality rate (%) Protective rate (%) The average survival time day (my god) Prolong vital rates (%) *Median effective dose (ED 50)
Silver horse antiviral drugs SHUANGHUANGLIAN KOUFUYE ribavirin virus control 4 2 1 0.5 4 2 1 0.5 0.1 0.05 0.025 10LD 50 30 30 30 30 30 30 30 30 30 30 30 30 0 1 7 13 7 11 13 20 0 0 6 28 100 97 75 54 75 60 54 28 100 100 78 14.0±0.00 13.7±1.46 12.5±2.82 10.5±4.17 12.17±3.4 11.13±3.91 10.33±4.31 8.73±4.20 14±0.00 14±0.00 12.97±2.84 6.23±2.36 125 120 101 69 95 79 66 40 125 125 108 ＜0.5 g/kg 0.76 g/kg ＜0.025 g/kg
*Calculate according to protective rate
3. after giving influenza virus, with pathological changes Mus lung suspension inoculated into chick embryo, detecting viral pneumonia is the indicator-specific statistics result, positive control drug SHUANGHUANGLIAN KOUFUYE and ribavirin.The results are shown in Table 9.
Resisiting influenza virus result of the test in the table 9 silver horse antiviral agents object
(with pathological changes Mus lung suspension inoculated into chick embryo, detecting viral pneumonia is index)
Medicine Dosage (g/kg) Number of mice (only) Viral pneumonia Viral pneumonia incidence rate (%) Viral pneumonia slip (%) Statistical procedures Interpretation of result * median effective dose (ED 50)
Have Do not have X 2 P
Silver horse antiviral drugs shuanghuanglian mixture, shuanghuanglian koufuye Ribavirin virus control 4 2 1 0.5 4 2 1 0.5 0.1 0.05 0.025 10LD 50 30 30 30 30 30 30 30 30 30 30 30 30 0 1 9 20 9 11 13 21 0 2 15 27 30 29 21 10 21 19 17 9 30 28 15 3 0 3.3 30 67 30 37 43 70 0 7 50 90 100 96 67 26 67 59 52 22 100 92 44 52.50 49.09 22.50 4.81 22.50 18.37 14.70 3.75 52.50 41.71 11.42 ＜0.01 ＜0.01 ＜0.01 ＜0.05 ＜0.01 ＜0.01 ＜0.01 ＞0.05 ＜0.01 ＜0.01 ＜0.01 Having obvious resisiting influenza virus effect to have obvious resisiting influenza virus effect to have obvious resisiting influenza virus effect to have the resisiting influenza virus effect to have obvious resisiting influenza virus effect to have obvious resisiting influenza virus effect to have obvious resisiting influenza virus effect not have the resisiting influenza virus effect has obvious resisiting influenza virus effect to have obvious resisiting influenza virus effect that the resisiting influenza virus effect is arranged 0.83 g/kg 0.97 g/kg 0.027 g/kg
*Calculate according to the viral pneumonia slip
(3), the test of the medicine efficacy screening of vitro inhibition SARS virus, carried out the inhibiting experiment to coronavirus No. 04 in African green monkey kidney passage cell (VERO E6 cell) is cultivated of silver-colored horse antiviral drugs, method and result are as follows:
Test method: pilot study: 1. silver-colored horse antiviral drugs is to the toxicity test of VERO E6 cell: VERO E6 cell is inoculated 96 well culture plates with 400,000/ml concentration, and 37 ℃, 5%CO 2Cultivated 24 hours, add the checking medicine, being tried thing silver horse antiviral drugs doubling dilution is 6000 μ g/ml ∽, 11.7 μ g/ml, the dilution of positive control medicine ganciclovir is 6000 μ g/ml ∽, 11.7 μ g/ml, every concentration is inoculated 3 holes, and every hole 100 μ l establish the normal cell contrast simultaneously, 37 ℃, 5%CO 2Cultivated 6 days, every day is observation of cell metamorphosis (CPE) under inverted microscope, is (+) with 25% following metamorphosis, 26 ∽ 50% are (++), 51 ∽ 75% are (+++), and 76 ∽ 100% are (++ ++), calculate medicine median toxic concentration (TD with the Reed-Muench method 50) and maximal non-toxic concentration (TD 0).2. in VERO E6 cell culture separation and the virulence of coronavirus No. 04 (No. 04 specimen of SARS patients serum is provided by You An hospital) are measured: VERO E6 cell is inoculated 96 test tubes with every milliliter 400,000 concentration, and 37 ℃, 5%CO 2Cultivated 24 hours, and discarded culture fluid, every pipe adds SARS patients serum 0.2ml, and 37 ℃ of rotary drums were cultivated 5 ∽ 7 days. and after the CPE variation appears in cell, adopt the method for PCR to detect coronavirus, No. 04 specimen PCR positive is defined as the coronavirus separated strain.With whole last dilution method purified virus 2 times, it is still positive that PCR detects coronavirus, through determination of immunofluorescence method double SARS patients serum, and the IgM positive, IgG4 doubly raises, and is defined as coronavirus.Adopting viral CPE method to measure it tires.Virus CPE method: VERO E6 cell is inoculated 96 culture plates with every milliliter 400,000 concentration, and 37 ℃, 5%CO 2Cultivated 24 hours, and added viral liquid, viral dilution 10 -1∽ 10 -6, 6 concentration, every concentration is inoculated 3 holes, and every hole 100 μ l establish the normal cell contrast, and 37 ℃, 5%CO 2Cultivated 5 ∽ 7 days, per 24 hours under inverted microscope the observed and recorded cellular morphology change (CPE): with 25% following metamorphosis is (+), and 26 ∽ 50% are (++), and 51 ∽ 75% are (+++), 76 ∽ 100% are (++ ++), calculate viral half with the Reed-Muench method and infect concentration TCID 50
Formal experiment: silver-colored horse antiviral drugs in VERO E6 cell culture to the inhibitory action of coronavirus No. 04:
VERO E6 cell is inoculated 96 well culture plates with every milliliter 400,000 concentration, and 37 ℃, 5%CO 2Cultivated 24 hours, cell culture discards culture fluid to monolayer, adds 100TCID 50Coronavirus liquid, establish normal cell contrast and virus control simultaneously.Put 37 ℃, 5%CO 2Adsorb after 2 hours, abandon viral liquid, add the silver-colored horse antiviral drugs of variable concentrations, the maximal non-toxic concentration (TD of choice of drug pair cell 0) i.e. 1500 μ g/ml ∽, the 2.93 μ g/ml of 10 concentration of 2 times of dilutions, positive control medicine ganciclovir is i.e. 6000 μ g/ml ∽, the 11.7 μ g/ml of 10 concentration of 2 times of dilutions, the medicine of dilution is added respectively in the cell hole, and every concentration 3 holes are established normal cell contrast and virus control simultaneously.Put 37 ℃, 5%CO 2Incubator was cultivated 5 ∽ 7 days, observed viral CPR day by day under inverted microscope, occurred with virus control +++-++ ++ in time, finish to test, and calculates the medium effective concentration (IC of medicine with the Reed-Muench method 50) and therapeutic index (TI), the test triplicate.
The result: silver-colored horse antiviral drugs is to the toxic action of VERO E6 cell, maximal non-toxic concentration (TD 0) be 1500 ± 0 μ g/ml, median toxic concentration (TD 50) be 3000 ± 0 μ g/ml; Contrast medicine ganciclovir maximal non-toxic concentration (TD 0) be＞6000 ± 0 μ g/ml, median toxic concentration (TD 50) be＞6000 ± 0 μ g/ml.
Silver horse antiviral drugs is cultivated in VERO E6 cell, to the inhibitory action of coronavirus No. 04, CPE method: medicine medium effective concentration (IC 50) be 375 ± 0 μ g/ml, minimum effective drug concentration (MIC) is 750 ± 0 μ g/ml; Contrast medicine ganciclovir CPE method: medicine medium effective concentration (IC 50) be 11.7 ± 0 μ g/ml, minimum effective drug concentration (MIC) is 23.44 ± 0 μ g/ml.
Anti-SARS virus result of the test shows, a little less than in VERO E6 cell, the inhibitory action comparison of coronavirus No. 04 being wanted according to the medicine ganciclovir of silver horse antiviral drugs, has only 1/32nd of contrast medicine, but, the treatment SARS there is assosting effect because it also has pharmacological actions such as heat-clearing and toxic substances removing, antiinflammatory be antibacterial.
2, antiinflammatory action:
(1), silver-colored horse antiviral drugs is to the influence of auricle inflammation due to the mice dimethylbenzene
All can be significantly after silver horse antiviral drugs 9.1,18.2g/kg and the administration of SHUANGHUANGLIAN KOUFUYE 12.0ml/kg group and highly significant suppress have significance meaning and highly significant meaning (P＜0.05 or P＜0.01) to see Table 10 with water group comparing difference by auricle inflammation due to the dimethylbenzene.
Table 10 silver horse antiviral drugs is to the influence of auricle inflammation due to the mice dimethylbenzene (X ± SD)
Group Dosage (g/kg) Number of animals (only) Inflammation swelling degree (mg) Inhibitory rate of intumesce (%)
Water group silver horse antiviral drugs silver horse antiviral drugs silver horse antiviral drugs SHUANGHUANGLIAN KOUFUYE 9.1 18.2 36.4 12.0ml/kg 10 10 10 10 10 8.2±3.3 4.0±3.7 * 3.2±2.1 ** 5.4±3.4 4.0±3.1 ** 51.2 61.0 34.1 51.2
Compare * P＜0.05, * * P＜0.01 with the water group.
(2), silver-colored horse antiviral drugs is to the granulomatous influence of rat agar
Silver horse antiviral drugs 4.55 and 9.1g/kg and SHUANGHUANGLIAN KOUFUYE 6ml/kg can be significantly and the highly significant inhibition by the granuloma due to the agar, itself and water group relatively have significant difference and significant differences (P＜0.05 and P＜0.01) sees Table 11.
Table 11 silver horse antiviral granule is to the granulomatous effect of rat agar (X ± SD)
Group Number of animals (only) Dosage (g/kg) Agar granuloma weight in wet base (g)
Water group silver horse antiviral drugs silver horse antiviral drugs silver horse antiviral drugs SHUANGHUANGLIAN KOUFUYE 10 10 10 10 10 4.55 9.10 18.2 6ml/kg 1.47±0.23 1.23±0.26 * 1.13±0.25 ** 1.32±0.36 1.13±0.38 *
Compare * P＜0.05, * * P＜0.01 with the normal saline group.
3, silver-colored horse antiviral drugs causes the influence of fever in rabbit body temperature to endotoxin
Only when 0.5h, significantly can suppress endotoxin after the silver horse antiviral drugs 3.64g/kg medication and cause fever in rabbits, compare (P＜0.05) with the water group; 7.28g/kg then 0.5,1,1.5,2h four time periods all can be significantly and highly significant suppress to cause fever in rabbits by endotoxin, with water group relatively (P＜0.05 and P＜0.01).And the aspirin group also can significantly suppress to cause fever in rabbits by endotoxin at 2.5h except that above-mentioned four time periods, compared (P＜0.05) with the water group and saw Table 12.
Table 12 silver horse antiviral granule is to influence (X ± SD) (n=7) of endotoxin pyrogenic rabbit body temperature
Group Dosage (g/kg) Different time body temperature changing value after the administration (℃)
0.5h 1h 1.5h 2h 2.5h 3h
Water group silver horse antiviral drugs silver horse antiviral drugs aspirin 3.64 7.28 0.1 1.16± 0.38 0.58± 0.45 * 0.59± 0.28 ** 0.59± 0.49 * 1.49± 0.50 1.16± 0.54 0.93± 0.38- 0.91± 0.33 * 1.48± 0.50 1.04± 0.33 0.83± 0.28 ** 0.79± 0.23 ** 1.14± 0.34 0.59± 0.58 0.52± 0.29 ** 0.56± 0.23 ** 0.75± 0.48 0.59± 0.36 0.33± 0.33 0.34± 0.11 * 0.66± 0.44 0.61± 0.58 0.27± 0.39 0.31± 0.31
Compare * P＜0.05, * * P＜0.01 with the normal saline group.
4, extracorporeal bacteria inhibitor test
Silver horse antiviral drugs all has in various degree bacteriostasis to the examination strain, is 0.125g/ml to the minimal inhibitory concentration (MIC) of staphylococcus aureus, beta hemolytic streptococcus, alpha streptococcus.Minimal inhibitory concentration (MIC) to bacillus pyocyaneus, Diplococcus pneumoniae sees Table 13 for 0.25g/ml.
The minimal inhibitory concentration (g/ml) of table 13 silver horse antiviral granule
Test organisms Silver horse antiviral drugs Extension rate
Golden yellow staphylococcus beta hemolytic streptococcus alpha streptococcus pyocyanic pneumonia diplococcus 0.125 0.125 0.125 0.25 0.25 1∶8 1∶8 1∶8 1∶4 1∶4
5, bacteriostatic test in the silver-colored horse antiviral agents object
Silver horse antiviral drugs 18.2g/kg and cefradine 0.30g/kg have stronger protective effect to the clinical bacteria of staphylococcus aureus, relatively have significant difference (P＜0.05) with the water group and see Table 14.
Bacteriostatic test in the table 14 silver horse antiviral agents object
Group Number of animals (only) Dosage (g/kg) Survival (only) Dead (only) Mortality rate (%)
Water group silver horse antiviral drugs silver horse antiviral drugs silver horse antiviral drugs cefradine 20 20 20 20 20 9.10 18.2 36.4 0.30 1 5 7 3 9 19 15 13 17 11 95 75 65 * 85 55 *
Compare * P＜0.05 with the water group.
6, silver-colored horse antiviral drugs is to the influence of mice delayed hypersensitivity
Remarkable and the highly significant inhibition mice ear of silver horse antiviral drugs 18.2g/kg and 36.4g/kg and SHUANGHUANLIAN 6.0ml/kg energy relatively has significant difference with model group and significant differences (P＜0.05 and P＜0.01) sees Table 15.
Table 15 silver horse antiviral drugs is to the influence of mice delayed hypersensitivity (X ± SD)
Group Dosage (g/kg) Number of animals (only) Two ear weight differences (mg)
Normal group model group silver horse antiviral drugs silver horse antiviral drugs silver horse antiviral drugs SHUANGHUANGLIAN KOUFUYE 9.1 18.2 36.4 6.0ml/kg 10 10 10 10 10 10 1.3±1.16 8.4±4.22 △△△ 7.1±2.38 4.7±3.33 * 3.3±2.58 ** 4.6±3.20 *
Compare with normal group △ △ △* P＜0.05, * * P＜0.01 are compared with model group in P＜0.01.
7, the analgesic activity of silver-colored horse antiviral drugs
(1) mice hot plate method test
Silver horse antiviral drugs 36.4 gram kilograms -1In the time of 30 minutes, can obviously improve the effect of the mice hot plate method threshold of pain, relatively have significant difference (P＜0.05) to see Table 16 with the water group.
Table 16 silver horse antiviral granule is to the influence of mice hot plate method pain threshold (X ± SD)
Group Number of animals (only) Dosage (g/kg) Before the administration Pain threshold after the administration
30 60 90 120
Physiological saline silver horse antiviral drugs silver horse antiviral drugs silver horse antiviral drugs aspirin 10 10 10 10 10 9.10 18.2 36.4 0.30 15.7± 5.02 16.2± 5.2 0 16.2± 484 16.5± 7.51 15.7± 5.56 11.5± 2.95 13.7± 4.20 13.4± 3.37 17.9± 9.42 * 19.1± 6.26 ** 13.3± 6.20 13.8± 6.26 13.3± 7.18 15.4± 11.9 19.6± 4.24 * 16.5± 8.45 13.9± 10.2 15.7± 6.90 18.3± 12.8 20.8± 5.27 17.5± 12.9 13.5± 6.25 15.4± 7.26 16.1± 8.68 21.5± 4.70
Compare with the normal saline group *P＜0.05, *P＜0.01.
(2) writhing method test
Lack than the water group though turn round the body number of times after the administration of silver horse antiviral drugs three dosage groups, relatively there are no significant that difference (P＞0.05) sees Table 17 with the water group.
Table 17 silver horse antiviral drugs Dichlorodiphenyl Acetate causes the influence (X ± SD) of mouse writhing reaction
Group Dosage (g/kg) Number of animals (only) Turn round body number of times (inferior/15 minute)
Water group silver horse antiviral drugs silver horse antiviral drugs silver horse antiviral drugs aspirin 9.10 18.2 36.4 0.30 11 11 11 11 11 15.1±11.3 10.6±8.87 11.9±9.99 12.2±9.53 6.27±5.12 *
Compare * P＜0.05 with the water group.
The specific embodiment
Embodiment 1
Press following proportioning weighting raw materials:
15 parts of 18 portions of Flos Loniceraes of 30 parts of Fructus Arctiis of Fructus Forsythiae
10 parts of 6 parts of Rhizoma Phragmitiss of 9 parts of Lasiosphaera Seu Calvatia of Rhizoma Belamcandae
(1), above Six-element crude drug adds 10 times of water gagings, heating extraction 3 times, each 1 hour, merge 3 times the water extract, filter, filtrate decompression concentrates;
(2), adding 95% ethanol, to transfer pure content be 50%, places, centrifugal;
(3), get supernatant and add the beta-schardinger dextrin-inclusion, stir evenly the back decompression and solvent recovery and be concentrated into relative density 1.10 -1.15, centrifugally going out beta-cyclo dextrin included compound, drying is pulverized, and crosses 80 mesh sieves, and with Icing Sugar, with the clear liquid one-step palletizing, packing promptly gets medicinal granule of the present invention.
Embodiment 2
Press following proportioning weighting raw materials:
12.48 parts of 15 portions of Flos Loniceraes of 25 parts of Fructus Arctiis of Fructus Forsythiae
6 parts of 7.52 parts of Rhizoma Phragmitiss of 7.52 parts of Lasiosphaera Seu Calvatia of Rhizoma Belamcandae
Step (1) and (2) are with embodiment 1, and prepared becomes capsule routinely then.
Embodiment 3
By following proportioning weighting raw materials
15 parts of 18 portions of Flos Loniceraes of 30 parts of Fructus Arctiis of Fructus Forsythiae
10 parts of 6 parts of Rhizoma Phragmitiss of 9 parts of Lasiosphaera Seu Calvatia of Rhizoma Belamcandae
Step (1) and (2) are with embodiment 1, and the supernatant decompression recycling ethanol concentrates then, and vacuum drying is pulverized, and add appropriate amount of starch and granulate, and tabletting becomes tablet.
Embodiment 4
By following proportioning weighting raw materials
15 parts of 18 portions of Flos Loniceraes of 30 parts of Fructus Arctiis of Fructus Forsythiae
10 parts of 6 parts of Rhizoma Phragmitiss of 9 parts of Lasiosphaera Seu Calvatia of Rhizoma Belamcandae
Step (1) and (2) are with embodiment 1, supernatant decompression recycling ethanol then, and regulating pH value is 7.2, adds water in right amount, makes oral liquid.
Embodiment 5
By following proportioning weighting raw materials
15 parts of 18 portions of Flos Loniceraes of 30 parts of Fructus Arctiis of Fructus Forsythiae
10 parts of 6 parts of Rhizoma Phragmitiss of 9 parts of Lasiosphaera Seu Calvatia of Rhizoma Belamcandae
Step (1) and (2) are with embodiment 1, and the supernatant decompression recycling ethanol concentrates then, and vacuum drying is ground into fine powder, and it is an amount of to add refined honey, makes concentrated pill.

Claims (19)

1, a kind of antiviral compound Chinese medicinal preparation is characterized in that said preparation made as follows by following raw medicaments in portion by weight:
5～25 parts of 6～30 portions of Flos Loniceraes of 10～50 parts of Fructus Arctiis of Fructus Forsythiae
1～10 part of 3～15 parts of Lasiosphaera Seu Calvatia of Rhizoma Belamcandae
(1), get the above-mentioned raw materials medicine, add 1～20 times of water gaging, heating extraction 3 times, each 0.5～3 hour, merge 3 times the water extract, filter, filtrate concentrates;
(2), adding 95% ethanol, to transfer pure content be 30～75%, places, centrifugal;
(3), get supernatant and add the beta-schardinger dextrin-inclusion, stir evenly the back decompression and solvent recovery and be concentrated into relative density 1.04～1.60, centrifugally go out beta-cyclo dextrin included compound, drying is pulverized, and crosses 80 mesh sieves;
(4), with above-mentioned dry thing, make acceptable various dosage forms on the pharmaceutics according to a conventional method.
2, preparation according to claim 1 is characterized in that the weight proportion of described crude drug is:
7.52 parts of 7.52 parts of Lasiosphaera Seu Calvatia of 12.48 parts of Rhizoma Belamcandae of 15 portions of Flos Loniceraes of 25 parts of Fructus Arctiis of Fructus Forsythiae.
3, preparation according to claim 1 is characterized in that crude drug wherein also can add 5～20 parts of Rhizoma Phragmitiss.
4, preparation according to claim 3 is characterized in that the weight proportion of described crude drug is:
10～20 parts of 9～24 portions of Flos Loniceraes of 15～40 parts of Fructus Arctiis of Fructus Forsythiae
7～15 parts of 3～8 parts of Rhizoma Phragmitiss of 5～12 parts of Lasiosphaera Seu Calvatia of Rhizoma Belamcandae.
5, preparation according to claim 4 is characterized in that the weight proportion of described crude drug is:
6 parts of 9 parts of Lasiosphaera Seu Calvatia of 15 parts of Rhizoma Belamcandae of 18 portions of Flos Loniceraes of 30 parts of Fructus Arctiis of Fructus Forsythiae
10 parts of Rhizoma Phragmitiss.
5, according to the arbitrary described preparation of claim 1-5, it is characterized in that: the dosage form of described preparation is granule, capsule, tablet, oral liquid, pill, suspensoid, drop pill, pellet, buccal tablet, soft gelatin capsule, soft capsule, dispersible tablet, solution, aerosol, spray, cataplasma or patch.
7, preparation according to claim 6 is characterized in that: described dosage form is a granule.
8, the preparation method of the described preparation of claim 7 is characterized in that comprising the following steps:
(1), get each crude drug, add 10 times of water gagings, heating extraction 3 times, each 1 hour, merge 3 times the water extract, filter, filtrate concentrates;
(2), adding 95% ethanol, to transfer pure content be 50%, places, centrifugal;
(3), get supernatant and add the beta-schardinger dextrin-inclusion, stir evenly the back and reclaim solvent and be concentrated into relative density 1.10～1.15, centrifugally go out beta-cyclo dextrin included compound, drying is pulverized, and crosses 80 mesh sieves, with Icing Sugar, with the clear liquid one-step palletizing, packing, promptly.
9, preparation method according to claim 8 is characterized in that: method for concentration wherein is to concentrate under the normal pressure.
10, preparation method according to claim 8 is characterized in that: method for concentration wherein is a concentrating under reduced pressure, and the concentrating under reduced pressure condition is: 0.01～0.09MPA, 40～90 ℃.
11, preparation method according to claim 10 is characterized in that: the condition of concentrating under reduced pressure is 70 ℃, 0.07MPA.
12, preparation method according to claim 8 is characterized in that: recovery solvent method wherein is a reclaim under reduced pressure.
13, preparation method according to claim 8 is characterized in that: recovery solvent method wherein is a reclaim under reduced pressure, and the condition of decompression and solvent recovery is: 0.01～0.09MPA, 30～80 ℃.
14, preparation method according to claim 13 is characterized in that: the condition of said decompression and solvent recovery is 70 ℃, 0.07MPA.
15, preparation method according to claim 8 is characterized in that: drying means wherein is contact drying, pneumatic conveying drying, tunnel type oven drying, vacuum decompression drying, airpillow-dry, spray drying, lyophilization, far-infrared ray drying or microwave drying.
16, the described preparation method of claim 8 is characterized in that: said drying means is 70-80 ℃ of oven dry.
17, the application of the arbitrary described antivirus compound formulation of claim 1-5 in preparation viral infection resisting medicine.
18, the application of the arbitrary described antivirus compound formulation of claim 1-5 in preparation preventing respiratory viruses infection medicine.
19, the application of the arbitrary described antivirus compound formulation of claim 1-5 in the anti-SARS viral infection ancillary drug of preparation.
CNB2004101008416A 2003-12-10 2004-12-07 Antivirus Chinese medicine compound preparation and its preparation method Expired - Fee Related CN1318077C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB2004101008416A CN1318077C (en) 2003-12-10 2004-12-07 Antivirus Chinese medicine compound preparation and its preparation method

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN200310111560 2003-12-10
CN200310111560.6 2003-12-10
CNB2004101008416A CN1318077C (en) 2003-12-10 2004-12-07 Antivirus Chinese medicine compound preparation and its preparation method

Publications (2)

Publication Number Publication Date
CN1650993A CN1650993A (en) 2005-08-10
CN1318077C true CN1318077C (en) 2007-05-30

Family

ID=34888149

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2004101008416A Expired - Fee Related CN1318077C (en) 2003-12-10 2004-12-07 Antivirus Chinese medicine compound preparation and its preparation method

Country Status (1)

Country Link
CN (1) CN1318077C (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100409863C (en) * 2005-11-24 2008-08-13 武汉思达创新医药科技有限公司 Use of shuanghuanglian for preparing medicine for treating arteriolar atherosis
CN102552807A (en) * 2012-01-10 2012-07-11 暨南大学 Chinese medicine for curing air temperature type flue and preparation method and application thereof
CN113274474A (en) * 2021-04-22 2021-08-20 王贵林 Plant antibiotic and preparation method and application thereof
CN115814049A (en) * 2022-12-12 2023-03-21 北京博奥晶方生物科技有限公司 Traditional Chinese medicine composition and preparation method and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1349821A (en) * 2001-11-01 2002-05-22 赵健忠 Pharyngitis treating Chinese medicine plaster

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1349821A (en) * 2001-11-01 2002-05-22 赵健忠 Pharyngitis treating Chinese medicine plaster

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
江西中医药 夏鑫华，5-6，伍炳彩运用银翘马勃散经验 2003 *

Also Published As

Publication number Publication date
CN1650993A (en) 2005-08-10

Similar Documents

Publication Publication Date Title
CN1733105B (en) Detection method of Golden Preparation for treating gynecological disease
CN101049424B (en) Medication for treating infection in respiratory system
CN105770207B (en) Viola yedoensis makino extract and application thereof
CN114053343B (en) Traditional Chinese medicine composition, preparation method and application
CN101040950B (en) Method of preparing compound Houttuynia cordata dropping pills
CN100500176C (en) Chinese medicine composition with functions of expelling surficial evils and clearing away heat and toxic materials and its preparing method and application
CN101683420A (en) Applications of traditional Chinese medicine composition in preparation of medicament for treating acute pharyngitis
CN112587595B (en) Traditional Chinese medicine composition for clearing heat and relieving exterior syndrome and preparation method thereof
CN1318077C (en) Antivirus Chinese medicine compound preparation and its preparation method
CN108524685A (en) A kind of composition that treating children's herpangina and its application
CN102908397B (en) Chinese herbal compound for treating wind-heat type common cold by dredging surfaces and releasing muscles and preparation thereof
CN104666431A (en) Traditional Chinese medicine preparation for treating acute upper respiratory tract infection and production method of traditional Chinese medicine preparation
CN101716300B (en) Cough relief traditional Chinese medicine compound preparation and preparation method thereof
CN108403858B (en) Callicarpa nudiflora extract composition for treating hand-foot-and-mouth disease and application thereof
CN102335373B (en) Chinese medicinal composition for treating upper respiratory tract infection, and preparation method thereof
CN111632116A (en) Preparation method of traditional Chinese medicine preparation for resisting viral cold
CN115869359B (en) Radix Scutellariae extract and its application
CN101683423B (en) Application of Chinese medicine composition in preparation of medicament for treating chicken pox
CN101721472B (en) Chinese medicine combination with health protection function
CN101209287A (en) Heat-clearing and detoxication antiphlogistic detumescence Chinese medicinal composition and preparation thereof
CN115105502B (en) Application of compound containing stephania plant alkaloid in preparation of cat infectious peritonitis medicine
CN101134092A (en) Traditional Chinese medicine compound preparations for treating respiratory disease and method for preparing the same
CN114984105A (en) Traditional Chinese medicine composition for treating cough variant asthma and preparation method thereof
CN103127313A (en) Lyophilized hemsley rockvine root tuber used for treating AIDS
CN1404868A (en) Chinese medicinal preparation for treating pyretic stranguria

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C41 Transfer of patent application or patent right or utility model
CB03 Change of inventor or designer information

Inventor after: Yu Hua

Inventor after: Jiang Yu

Inventor after: Wang Youzhi

Inventor after: Zhong Xiaoqun

Inventor after: Zhang Aihua

Inventor after: Fang Lv

Inventor after: Li Yuyun

Inventor after: Zhang Junming

Inventor after: Weng Xiuying

Inventor after: Wang Decai

Inventor after: Fan Xueliang

Inventor before: Yu Hua

Inventor before: Zhong Xiaoqun

Inventor before: Zhang Aihua

Inventor before: Fang Lv

Inventor before: Li Yuyun

Inventor before: Zhang Junming

Inventor before: Weng Xiuying

COR Change of bibliographic data
TR01 Transfer of patent right

Effective date of registration: 20151229

Address after: 214000 No. 6 Jun Road, Wuxi national hi tech Industrial Development Zone, Jiangsu, Wuxi

Patentee after: JIANGSU LINGBAO PHARMACEUTICAL Co.,Ltd.

Address before: 330029 No. 181 East Nanjing Road, East Lake District, Jiangxi, Nanchang

Patentee before: JIANGXI INST OF MATERIA MEDICA

PP01 Preservation of patent right
PP01 Preservation of patent right

Effective date of registration: 20191127

Granted publication date: 20070530

PD01 Discharge of preservation of patent
PD01 Discharge of preservation of patent

Date of cancellation: 20221127

Granted publication date: 20070530

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070530